Zug, Switzerland, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important medical needs in otolaryngology, today announced that it will release its financial results for the third quarter 2015 on Thursday, November 12, 2015. Following the announcement, Auris Medical's management will host a live conference call and webcast at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time) to discuss Auris Medical's financial results for the third quarter 2015 and provide a general business update.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Contact: Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94, ear@aurismedical.com
Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685, matthew@lifesciadvisors.com
Auris Medical Q3 2015 Earnings Release Date 2015-05-11 http://hugin.info/160190/R/1964528/717079.pdf
HUG#1964528
